← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,992	+266	+10%	$267B
2	2 Merck MRK $364B	2,538	+231	+10%	$175B
3	3 Pfizer PFE $166B	2,526	+202	+9%	$157B
4	4 AbbVie ABBV $501B	2,244	+241	+12%	$94.8B
5	5 Bristol-Myers Squibb BMY $121B	2,219	+404	+22%	$113B
6	6 Amgen AMGN $230B	2,108	+224	+12%	$110B
7	7 Gilead Sciences GILD $190B	1,557	+93	+6%	$66.2B
8	8 Novartis NVS $279B	1,173	+82	+8%	$24.4B
9	9 GSK GSK $95.9B	895	+89	+11%	$13.5B
10	10 Regeneron Pharmaceuticals REGN $80.1B	703	+70	+11%	$27.7B
11	11 AstraZeneca AZN $251B	635	+79	+14%	$22.3B
12	12 Incyte INCY $22.6B	556	+59	+12%	$17.2B
13	13 DELISTED Exact Sciences EXAS	527	+52	+11%	$12.1B
14	14 Jazz Pharmaceuticals JAZZ $13.6B	446	+40	+10%	$7.76B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	396	+70	+21%	$18.6B
16	16 Takeda Pharmaceutical TAK $60.7B	339	+22	+7%	$2.57B
17	17 Exelixis EXEL $15.1B	329	-11	-3%	$4.17B
18	18 Qiagen QGEN $9.41B	297	+53	+22%	$5.13B
19	19 Guardant Health GH $21.9B	268	+26	+11%	$6.03B
20	20 NeoGenomics NEO $2.17B	261	+8	+3%	$2.73B
21	21 DELISTED Blueprint Medicines BPMC	228	+8	+4%	$4.06B
22	22 Myriad Genetics MYGN $397M	227	+6	+3%	$2.15B
23	23 Halozyme HALO $13.3B	224	+14	+7%	$2.27B
24	24 BeOne Medicines Ltd ONC $39.8B	221	+25	+13%	$8.11B
25	25 Kyntra Bio KYNB $22.5M	213	+3	+1%	$2.63B